Jeffrey W. Henderson has served on the Halozyme Board of Directors since 2015 and has been the independent Board Chair since May 2022. He brings over 30 years of financial, commercial and pharmaceutical industry expertise, and has completed the NACD/Carnegie Mellon University CERT Certificate in Cyber-Risk Oversight program for governance professionals.
Mr. Henderson has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018, and served as a Healthcare Advisory Director to Berkshire Partners LLC from 2015 to 2019. He previously served as Chief Financial Officer of Cardinal Health, Inc. from May 2005 to November 2014, remaining in an executive capacity until his retirement in August 2015. From 1998 to 2005 he held various senior management positions at Eli Lilly and Company, including President and General Manager of Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc.
He received his B.S. in electrical engineering from Kettering University, Flint, Michigan, and his M.B.A. from Harvard Graduate School of Business Administration.